NRx Pharmaceuticals (NRXP) announced the appointment of Glenn Tyson as the company’s first chief commercial officer. As NRx looks forward to the anticipated approval of its abbreviated new drug application for their preservative-free ketamine product, it looks to build its commercial capabilities and prepare for a successful launch. Most recently, Tyson has focused on the emerging sector of companies developing neuroplastic therapies for psychiatric conditions, including leadership level work with Transcend Therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- Psychedelic: AtaiBeckley reports publication of BPL-003 study results
- NRx Pharmaceuticals announces FDA labeling alignment for ketamine product
- Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
- Nrx Pharmaceuticals’ Earnings Call Signals High‑Stakes Progress
- Psychedelic: Compass Pathways, NRx Pharma report earnings results